Table 2.
Timing relative to PHV (yrs) | ||||
---|---|---|---|---|
Stage | Samples (n) | Mean | 95% confidence interval | Range |
Female patients | ||||
0 | 56 | -5.18 | -5.52 to -4.84 | -7.57 to -2.23 |
1 | 40 | -2.82 | -3.18 to -2.46 | -5.15 to -0.61 |
2 | 48 | -1.79 | -2.06 to -1.51 | -3.78 to 0.04 |
3 | 39 | -0.51 | -0.78 to -0.23 | -1.99 to 1.05 |
4 | 88 | 0.71 | 0.50 to 0.93 | -2.18 to 2.93 |
5* | 26 | 4.10 | 3.53 to 4.67 | 1.55 to 6.89 |
Male patients | ||||
0 | 46 | -4.78 | -5.25 to -4.31 | -8.55 to -1.69 |
1 | 27 | -2.29 | -2.71 to -1.87 | -4.66 to -0.57 |
2 | 39 | -1.80 | -2.12 to -1.48 | -4.55 to 0.31 |
3 | 40 | -0.67 | -0.96 to -0.39 | -3.50 to 0.96 |
4 | 91 | 0.72 | 0.52 to 0.92 | -1.76 to 2.43 |
5* | 9 | 3.32 | 2.66 to 3.98 | 2.12 to 5.08 |
first appearance of stage 5; there were 179 metaphysis, epiphysis hook skeletal assessment stage 5 radiographs that were made after the first appearance of stage 5 and were not used for calculations of the first appearance of stage 5